{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:17:00Z","timestamp":1783138620834,"version":"3.54.6"},"reference-count":37,"publisher":"Japanese Society of Internal Medicine","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,7,1]]},"DOI":"10.2169\/internalmedicine.6217-25","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T22:07:33Z","timestamp":1764194853000},"page":"1754-1763","source":"Crossref","is-referenced-by-count":0,"title":["A Retrospective Study of 116 Multiple Sclerosis Patients with Dimethyl Fumarate Treatment in a Single Institution in Japan"],"prefix":"10.2169","volume":"65","author":[{"given":"Shoki","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan"},{"name":"Sapporo Neurology Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Uwatoko","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan"},{"name":"Sapporo Neurology Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Yaguchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan"},{"name":"Sapporo Neurology Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moemi","family":"Yamada","sequence":"additional","affiliation":[{"name":"Sapporo Neurology Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Sato","sequence":"additional","affiliation":[{"name":"Sapporo Neurology Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Sapporo Neurology Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Fukazawa","sequence":"additional","affiliation":[{"name":"Sapporo Neurology Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Yabe","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Browne P, Chandraratna D, Angood C, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology 83: 1022-1024, 2014.","DOI":"10.1212\/WNL.0000000000000768"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83: 278-286, 2014.","DOI":"10.1212\/WNL.0000000000000560"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lizak N, Malpas CB, Sharmin S, et al. Association of sustained immunotherapy with disability outcomes in patients with active secondary progressive multiple sclerosis. JAMA Neurol 77: 1398-1407, 2020.","DOI":"10.1001\/jamaneurol.2020.2453"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Capra R, Cordioli C, Rasia S, Gallo F, Signori A, Sormani MP. Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS. Mult Scler 23: 1757-1761, 2017.","DOI":"10.1177\/1352458516687402"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Koch-Henriksen N, Laursen B, Stenager E, Magyari M. Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study. J Neurol Neurosurg Psychiatry 88: 626-631, 2017.","DOI":"10.1136\/jnnp-2017-315907"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Chalmer TA, Baggesen LM, N\u00f8rgaard M, et al. Early versus later treatment start in multiple sclerosis: a register-based cohort study. Eur J Neurol 25: 1262-e1110, 2018.","DOI":"10.1111\/ene.13692"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Spelman T, Magyari M, Piehl F, et al. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies. JAMA Neurol 78: 1197-1204, 2021.","DOI":"10.1001\/jamaneurol.2021.2738"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Iaffaldano P, Lucisano G, Caputo F, et al. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord 14: 17562864211019574, 2021.","DOI":"10.1177\/17562864211019574"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol 76: 536-541, 2019.","DOI":"10.1001\/jamaneurol.2018.4905"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134 (Pt 3): 678-692, 2011.","DOI":"10.1093\/brain\/awq386"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther 341: 274-284, 2012.","DOI":"10.1124\/jpet.111.190132"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Chen H, Assmann JC, Krenz A, et al. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. J Clin Invest 124: 2188-2192, 2014.","DOI":"10.1172\/JCI72151"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Gold R, Arnold DL, Bar-Or A, et al. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results. Mult Scler 28: 801-816, 2022.","DOI":"10.1177\/13524585211037909"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17: 162-173, 2018.","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lorscheider J, Buzzard K, Jokubaitis V, et al. Defining secondary progressive multiple sclerosis. Brain 139 (Pt 9): 2395-2405, 2016.","DOI":"10.1093\/brain\/aww173"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Frau J, Sormani MP, Signori A, et al. Clinical activity after fingolimod cessation: disease reactivation or rebound? Eur J Neurol 25: 1270-1275, 2018.","DOI":"10.1111\/ene.13694"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hatcher SE, Waubant E, Nourbakhsh B, Crabtree-Hartman E, Graves JS. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol 73: 790-794, 2016.","DOI":"10.1001\/jamaneurol.2016.0826"},{"key":"18","unstructured":"18. Collaborators GMS. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18: 269-285, 2019."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Houzen H, Kano T, Kondo K, Takahashi T, Niino M. The prevalence and incidence of multiple sclerosis over the past 20 years in northern Japan. Mult Scler Relat Disord 73: 104696, 2023.","DOI":"10.1016\/j.msard.2023.104696"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Houzen H, Niino M, Kikuchi S, et al. The prevalence and clinical characteristics of MS in northern Japan. J Neurol Sci 211 (1-2): 49-53, 2003.","DOI":"10.1016\/S0022-510X(03)00033-9"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Houzen H, Niino M, Hata D, et al. Increasing prevalence and incidence of multiple sclerosis in northern Japan. Mult Scler 14: 887-892, 2008.","DOI":"10.1177\/1352458508090226"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Houzen H, Niino M, Hirotani M, et al. Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan. J Neurol Sci 323 (1-2): 117-122, 2012.","DOI":"10.1016\/j.jns.2012.08.032"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Houzen H, Kondo K, Horiuchi K, Niino M. Consistent increase in the prevalence and female ratio of multiple sclerosis over 15 years in northern Japan. Eur J Neurol 25: 334-339, 2018.","DOI":"10.1111\/ene.13506"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Prosperini L, Lucchini M, Ruggieri S, et al. Shift of multiple sclerosis onset towards older age. J Neurol Neurosurg Psychiatry 2022.","DOI":"10.1136\/jnnp-2022-329049"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Thompson MT, Virginia D, Nick B, et al. Adherence and discontinuation rates in patients on Tecfidera\u2122 (dimethyl fumarate): long-term Canadian experience from the Biogen ONE\u2122 support program. Mult Scler Relat Disord 67: 104080, 2022.","DOI":"10.1016\/j.msard.2022.104080"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Roar M, Nielsen ARH, Berg JM, et al. Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study. Mult Scler Relat Disord 80: 105127, 2023.","DOI":"10.1016\/j.msard.2023.105127"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Sato K, Niino M, Kawashima A, Yamada M, Miyazaki Y, Fukazawa T. Disease exacerbation after the cessation of fingolimod treatment in Japanese patients with multiple sclerosis. Intern Med 57: 2647-2655, 2018.","DOI":"10.2169\/internalmedicine.0793-18"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Graves JS, Krysko KM, Hua LH, Absinta M, Franklin RJM, Segal BM. Ageing and multiple sclerosis. Lancet Neurol 22: 66-77, 2023.","DOI":"10.1016\/S1474-4422(22)00184-3"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol 15: 287-300, 2019.","DOI":"10.1038\/s41582-019-0170-8"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367: 1098-1107, 2012.","DOI":"10.1056\/NEJMoa1114287"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Sejbaek T, Nybo M, Petersen T, Illes Z. Real-life persistence and tolerability with dimethyl fumarate. Mult Scler Relat Disord 24: 42-46, 2018.","DOI":"10.1016\/j.msard.2018.05.007"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Theodore Phillips J, Erwin AA, Agrella S, et al. Consensus management of gastrointestinal events associated with delayed-release dimethyl fumarate: a delphi study. Neurol Ther 4: 137-146, 2015.","DOI":"10.1007\/s40120-015-0037-x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Phillips JT, Hutchinson M, Fox R, Gold R, Havrdova E. Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: experiences of an international panel. Mult Scler Relat Disord 3: 513-519, 2014.","DOI":"10.1016\/j.msard.2014.03.003"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Reder AT, Centonze D, Naylor ML, et al. COVID-19 in patients with multiple sclerosis: associations with disease-modifying therapies. CNS Drugs 35: 317-330, 2021.","DOI":"10.1007\/s40263-021-00804-1"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Greenfield J, Metz LM, Khakban A, et al. Cancer risk, disease-modifying therapy, and age in multiple sclerosis: a retrospective population-based cohort study. Mult Scler Relat Disord 80: 105091, 2023.","DOI":"10.1016\/j.msard.2023.105091"},{"key":"36","unstructured":"36. Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391: 1263-1273, 2018."},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Cross AH, Delgado S, Habek M, et al. COVID-19 outcomes and vaccination in people with relapsing multiple sclerosis treated with ofatumumab. Neurol Ther 11: 741-758, 2022.","DOI":"10.1007\/s40120-022-00341-z"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/13\/65_6217-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T03:28:44Z","timestamp":1783135724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/13\/65_6217-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":37,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6217-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"6217-25"}}